Detalhe da pesquisa
1.
Prodromal depression and anxiety are associated with worse treatment compliance and survival among patients with pancreatic cancer.
Psychooncology
; 31(8): 1390-1398, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35470512
2.
Targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer.
bioRxiv
; 2023 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37034685
3.
Increased glucose availability sensitizes pancreatic cancer to chemotherapy.
Nat Commun
; 14(1): 3823, 2023 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37380658
4.
Clinical development of IDH1 inhibitors for cancer therapy.
Cancer Treat Rev
; 103: 102334, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34974243
5.
IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression.
Mol Cancer Ther
; 21(12): 1810-1822, 2022 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36190971
6.
Wild-type IDH1 inhibition enhances chemotherapy response in melanoma.
J Exp Clin Cancer Res
; 41(1): 283, 2022 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36153582
7.
Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors.
Nat Cancer
; 3(7): 852-865, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35681100